top of page

BRIDGE

PHASE II TRIAL OF DURVALUMAB AND CHEMOTHERAPY INDUCTION FOLLOWED BY DURVALUMAB AND RADIOTHERAPY IN LARGE VOLUME STAGE III NSCLC

NSCLC

3

65

II

Spain, France, Italy

Recruitment

CLINICAL TRIAL DETAILS

STAGE III A-B-C (ACCORDING TO VERSION 8 OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER STAGING MANUAL IN THORACIC ONCOLOGY) NSCLC PATIENTS NOT ELIGIBLE FOR SURGERY OR CONCURRENT CHEMORADIATION AT DIAGNOSIS BECAUSE OF LARGE TUMOR VOLUMES. THIS IS A MULTICENTRIC, OPEN LABEL, SINGLE ARM, SIMON 2 STAGES PHASE 2 TRIAL.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

PRESS RELEASE

home_fondo_you_barra.jpg

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

PHERGAIN SITES

home_fondo_you_barra.jpg
Vall d'Hebron Institute of Oncology (VHIO) (Spain) | Gustave Roussy (France) | Institute Tumori Mario Negrini (Italy)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page